Novartis

News

MS research network taps Seqster for data sharing

A research initiative in multiple sclerosis launched with support from Novartis has partnered with Seqster to provide a unified platform for data sharing, supporting patie

News

Sanofi trumpets win for oral BTK drug in chronic hives

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a w

News

Roche’s Xolair is first medicine for food allergy in US

Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people w

News

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around

News

Novartis calls time on Tim3 drug sabatolimab in MDS

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.

News

Sandoz makes its first post-spinout acquisition

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in

MS research network taps Seqster for data sharing

Sanofi trumpets win for oral BTK drug in chronic hives

Roche’s Xolair is first medicine for food allergy in US

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

Novartis calls time on Tim3 drug sabatolimab in MDS

Sandoz makes its first post-spinout acquisition

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

Novartis

Editor's Picks